by David Kent | Feb 2, 2015
> As many of our readers are aware, the Network of Centre of Excellence known as the Stem Cell Network (SCN), which was created in 2001, will wind down the majority of it’s activities this year. I have been a trainee/alumnus since the start of my PhD in 2003 and...
by Peter Raaymakers | Jan 30, 2015
Click image to go to CTV News Ottawa video We’ve written about some questionable “clinical trials” recruiting patients in Canada recently, so it only makes sense to follow-up with some hopeful news about a legitimate,...
by James Smith | Jan 26, 2015
With contributions from David Brindley . Cell-based treatments are being developed and marketed for a variety of indications: from rare orphan diseases like graft versus host disease (GvHD), to blockbuster conditions like diabetes and cardiovascular disease that...
by Stacey Johnson | Jan 23, 2015
. Signals’ mandate is to bring you, dear reader, blogs about stem cells, commercialization and biomaterials, but lately there hasn’t been much of the latter; therefore, I’ve decided to try to fill that gap. But before you get too excited, I am in no way an expert on...
by Stacey Johnson | Jan 20, 2015
. Before you read my blog, I recommend that you first read Sara Nolte’s blog “Bad luck, bad science, or bad reporting?” In it, Sara does an excellent job explaining and commenting on Drs. Cristian Tomasetti’s and Bert Vogelstein’s study “Variation in cancer risk among...
by Sara M. Nolte | Jan 19, 2015
. If you’ve been on the Internet at all in 2015, you’ve probably stumbled across headlines like “Two-thirds of cancers are due to ‘back luck,’ study finds” (CBSNews), “Most cancers are caused by bad luck not genes or lifestyle say scientists” (The Telegraph), “Cause...
by Lisa Willemse | Jan 16, 2015
> There are few things in Canada that grab national attention than a story related to hockey. News that surfaced last month that hockey legend Gordie Howe had received an unproven stem cell therapy for stroke continue to grab headlines in this country. In the past...
by Mark Curtis | Jan 13, 2015
. Welcome to your Update from the Clinic for the month of December. bluebird bio’s first four patients are transfusion-free after treatment with its gene therapy Lentiglobin. Fate Therapeutics’ hematopoietic stem cell-modulating technology ProHema seems to be on track...
by Stacey Johnson | Jan 9, 2015
. Alzheimer’s disease is a chronic, neurodegenerative disease characterized by loss of memory and changes in behaviour in the early stage. It typically starts slowly and progresses, within a decade, to death from an external factor, such as an infection or pneumonia,...
by Mark Curtis | Jan 7, 2015
. Welcome to your deal review for the month of December. Juno Therapeutics made its leap into the public realm with the largest biotech initial public offering (IPO) in 2014. bluebird Bio announced pricing of a common offering to raise over $200M. Read on to find out...
Comments